What Happened
- Prime Minister Modi, addressing a post-Budget webinar on "Sustaining and Strengthening Economic Growth," called on industry and MSMEs to "build more, produce more, connect more, and export more."
- He identified biopharma as a strategic priority sector, positioning it at the centre of India's next phase of manufacturing-led growth.
- The Union Budget 2026-27 announced the Biopharma SHAKTI Mission — an allocation of ₹10,000 crore over five years — to make India a global hub for biologics and next-generation therapies.
- SHAKTI stands for Strategy for Healthcare Advancement through Knowledge, Technology, and Innovation.
- Modi stated that India wants to "become leaders in advanced biopharma research and manufacturing," noting that the global supply chain is being reshaped and India must seize the moment as a "trustworthy and resilient manufacturing partner."
- The Budget also proposes setting up over 1,000 accredited India Clinical Trials (ICT) sites and strengthening the Central Drugs Standard Control Organisation (CDSCO).
- Three new National Institutes of Pharmaceutical Education and Research (NIPERs) are to be established, with seven existing ones upgraded.
Static Topic Bridges
India's Pharmaceutical Sector: From Generics to Biologics
India is known as the "pharmacy of the world," supplying approximately 20% of global generic medicine volumes and around 60% of global vaccine supply. However, the biologics and biosimilars segment — which includes insulin, monoclonal antibodies, and gene therapies — represents a higher-value frontier where India has historically lagged behind the US, EU, and China.
- India's pharmaceutical exports stood at approximately $27.8 billion in 2024-25.
- Biologics are large-molecule drugs derived from living cells; biosimilars are near-copies approved after patent expiry.
- India currently produces biosimilars for trastuzumab (cancer), bevacizumab, and insulin but lacks a dominant global position in novel biologics.
- The Production Linked Incentive (PLI) Scheme for pharmaceuticals (₹15,000 crore) launched in 2021 targeted bulk drugs and medical devices; SHAKTI now extends this logic to biologics.
- CDSCO is India's drug regulatory body, equivalent to the US FDA.
Connection to this news: The Biopharma SHAKTI Mission signals a strategic upgrade: India aims to move beyond generics and become a first-mover in biologics manufacturing, particularly as global supply chains diversify away from China post-COVID-19.
Industrial Policy and Export Promotion in India
Industrial policy refers to government strategies to influence the development of specific sectors through incentives, regulation, and public investment. India's industrial policy has evolved from import substitution (pre-1991) to liberalisation and now a neo-mercantilist export-promotion model.
- Key instruments: PLI schemes (14 sectors, ~₹2 lakh crore total outlay), Special Economic Zones (SEZs), Export Promotion Councils.
- India's merchandise exports target: $1 trillion by 2030 (set under the Foreign Trade Policy 2023).
- The PM Gati Shakti National Master Plan (2021) integrates infrastructure for logistics efficiency, a prerequisite for export competitiveness.
- MSMEs account for ~45% of India's exports; the post-Budget webinar specifically addressed MSME participation in the export push.
- "China+1" strategy: global companies diversifying supply chains from China, creating an opportunity for India in electronics, pharma, and textiles.
Connection to this news: Modi's call for an export push reflects India's broader industrial policy pivot — using budget allocations like SHAKTI to build sectors where India can capture a disproportionate share of global supply chain reorganisation.
Clinical Trials Regulation and Drug Approval Framework
Clinical trials are controlled research studies on human subjects to evaluate the safety and efficacy of drugs, biologics, or medical devices. India's regulatory framework for clinical trials is governed by the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.
- CDSCO (under Ministry of Health) is the apex regulatory body; its Scientific Review Cadre is proposed to be strengthened under SHAKTI.
- India has significant advantages for clinical trials: large, genetically diverse population; lower trial costs than Western countries; established hospital networks.
- A 2022 Niti Aayog report noted regulatory bottlenecks as a key barrier to India becoming a global clinical trial hub.
- Strengthening 1,000+ ICT sites and CDSCO capacity are prerequisites for attracting global Phase I-III trials to India.
Connection to this news: The SHAKTI Mission's investment in clinical trial infrastructure directly addresses India's regulatory and capacity gaps, which have historically caused global pharma companies to conduct trials elsewhere despite India's population advantage.
Key Facts & Data
- Biopharma SHAKTI Mission: ₹10,000 crore over five years (Union Budget 2026-27).
- SHAKTI: Strategy for Healthcare Advancement through Knowledge, Technology, and Innovation.
- India's pharma exports: ~$27.8 billion (2024-25); target of $65 billion by 2047 (Pharma Vision 2047).
- 3 new NIPERs to be established; 7 existing ones to be upgraded.
- 1,000+ accredited India Clinical Trials (ICT) sites to be created.
- CDSCO to get a dedicated Scientific Review Cadre for global-timeline drug approvals.
- India supplies ~20% of global generic medicine volumes and ~60% of global vaccine supply.
- PLI Scheme for pharmaceuticals (2021): ₹15,000 crore for bulk drugs and medical devices.